ERIS Eris Lifesciences Q4 FY25 results (Jan–Mar 2025) and concall
ERIS delivered a strong Q4 and full-year FY25 performance, characterized by robust revenue growth and substantial margin expansion following the integration of Biocon and Swiss Parenterals. The company is successfully transitioning to in-house manufacturing, aiming for 80% in-house production by the end of FY26. With a clear focus on the 'Diabesity' segment and a strong pipeline of GLP-1 and Insulin analogs, ERIS is positioning itself to become the #3 player in the Indian anti-diabetes market within three years.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 400 | 405 |
| EBITDA | 100 | 121 |
| Net profit | 2 | 30 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
